Navigation Links
Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
Date:9/16/2008

Human trials show that Emulin(TM), a plant-based extract, is better than metformin, the leading Type 2 diabetes medication, at controlling blood sugar levels in human beings.

Winter Haven, FL (PRWEB) September 16, 2008 -- A newly developed plant extract can regulate blood sugar levels in Type 2 diabetics better than a leading prescription drug, according to the results of human trials released today.

The trial results involving Emulin™, an all-natural compound derived from tropical fruits, are even more significant now that major research shows just how critical it is for diabetics to control long-term blood sugar levels to stave off heart attacks and other complications of this disease.

"The results show that Emulin™ alone is better than the leading prescription drug at reducing blood glucose levels in Type 2 diabetics," said Daryl Thompson, a scientific director at www.atmmetabolics.com [ATM Metabolics]], the Winter Haven Fla.-based firm that developed the food additive. "With the numbers of diabetics worldwide expected to grow from an estimated 150 million now to 300 million by 2025, the market for Emulin™ is staggering."

According to Thompson, the plant-derived compound acts like insulin when ingested. "We designed Emulin™ to lessen the glycemic impact of high-sugar foods like colas and candies or high-carbohydrate refined breads," Thompson said.

In a double-blind, placebo-controlled, FDA-approved human trial, 40 Type 2 diabetics consumed three time a day (before each meal) a capsule containing either 250 mg of Emulin™ or a placebo. Participants were divided into four sub-groups: placebo only; placebo and metformin, a leading prescription medication to control glucose absorption in Type 2 diabetics; Emulin™ only; and Emulin™ with metformin.

The study was discontinued after one week for the two groups taking metformin, and after two weeks for the other groups.

At the end of one week, fasting blood glucose levels remained the same or increased slightly for the placebo control group and decreased 2 percent in the metformin only group. Fasting blood glucose levels decreased 11 percent and 28 percent respectively, however, for the Emulin™ only group and the Emulin™ plus metformin group.

After one week, peak blood sugar level, meaning the level two hours after a glucose tolerance test, increased 4 percent in the placebo only group, was unchanged in the Emulin™ only group; and decreased 10 percent in the metformin only group and 12 percent in the metformin plus Emulin™ group.

At the end of two weeks, both fasting blood glucose and peak blood glucose had increased 1 percent in the placebo only group yet declined 20 percent in the Emulin™ only group.

The study results will be presented formally during the UCLA Symposium on Metabolic Diseases in January 2009. The independent company that conducted the human trial is dgd Research, Inc., of San Antonio, Texas.

About ATM Metabolics
ATM Metabolics is an early stage technology development and commercialization company focused on technologies for diabetic, nutrition, and diet products. The firm constantly researches and develops novel therapeutics for conditions that include Types 1 and 2 diabetes and other chronic or debilitating conditions. More information: http://www.atmmetabolics.com.

# # #

Read the full story at http://www.prweb.com/releases/2008/09/prweb1335264.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments ... Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to ... more. Expo attendees can stop by booth 1021 to learn how Shimadzu’s instruments ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) announced today that Martine Rothblatt , ... will provide an overview and update on the company,s ... Health Care Conference. The presentation will take ... Eastern Time, and can be accessed via a live ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI ... testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers a solution ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
Breaking Biology News(10 mins):